2138442-13-2
Chemical Structure
Vibecotamab
Synonym(s): XmAb14045
- CAS No.: 2138442-13-2
- Formula:N/A
- Molecular Weight:(126.15 kDa)
IUPAC Name: (2-amino-7-(trifluoromethyl)benzo[d]thiazol-4-yl)boronic acid
SMILES: [Vibecotamab]
Biological Activity: Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vibecotamab | 99.34% | Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. FarhadRavandiMBBS, et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study. Blood, Volume 136, Supplement 1, 5 November 2020, Pages 4-5
- [2]. Nicholas James Short et al., Meeting Abstract: 2023 ASCO Annual Meeting I, Journal of Clinical Oncology, Volume 41, Number 16
- [3]. Seung Y. Chu, et al., (2014) Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia, Blood, Volume 124, Issue 21, Page 2316, ISSN 0006-4971.
